ES2055904T3 - Composiciones para suministro de farmacos. - Google Patents

Composiciones para suministro de farmacos.

Info

Publication number
ES2055904T3
ES2055904T3 ES90903612T ES90903612T ES2055904T3 ES 2055904 T3 ES2055904 T3 ES 2055904T3 ES 90903612 T ES90903612 T ES 90903612T ES 90903612 T ES90903612 T ES 90903612T ES 2055904 T3 ES2055904 T3 ES 2055904T3
Authority
ES
Spain
Prior art keywords
drugs
compositions
supply
composition
active compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90903612T
Other languages
English (en)
Other versions
ES2055904T5 (es
Inventor
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10652342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2055904(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Danbiosyst UK Ltd filed Critical Danbiosyst UK Ltd
Publication of ES2055904T3 publication Critical patent/ES2055904T3/es
Application granted granted Critical
Publication of ES2055904T5 publication Critical patent/ES2055904T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

UNA COMPOSICION PARA ADMINISTRAR EN LA MUCOSA CONSTA DE UN COMPUESTO FARMACOLOGICAMENTE ACTIVO Y UNA SUSTANCIA POLICATIONICA. LA SUSTANCIA POLICATIONICA ES PREFERIBLEMENTE ES DEXTRANO-DEAE O QUITOSANO Y EL COMPUESTO FARMACOLOGICAMENTE ACTIVO ES PREFERIBLEMENTE INSULINA O CLACITONINA. LA COMPOSICION PUEDE PRESENTARSE COMO SOLUCION, DISPERSION, POLVO O MICROESFERAS. OTROS INTENSIFICADORES, TAL COMO LISOFOSFATIDILCOLINA PUEDEN INCLUIRSE SI SE DESEA.
ES90903612T 1989-02-25 1990-02-23 Composiciones para suministro de farmacos. Expired - Lifetime ES2055904T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898904370A GB8904370D0 (en) 1989-02-25 1989-02-25 Liquid delivery compositions

Publications (2)

Publication Number Publication Date
ES2055904T3 true ES2055904T3 (es) 1994-09-01
ES2055904T5 ES2055904T5 (es) 1998-01-01

Family

ID=10652342

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90903612T Expired - Lifetime ES2055904T5 (es) 1989-02-25 1990-02-23 Composiciones para suministro de farmacos.

Country Status (10)

Country Link
EP (1) EP0460020B2 (es)
JP (1) JP3306779B2 (es)
AT (1) ATE104545T1 (es)
CA (1) CA2045472C (es)
DE (1) DE69008346T3 (es)
DK (1) DK0460020T3 (es)
ES (1) ES2055904T5 (es)
GB (1) GB8904370D0 (es)
NO (1) NO301692B1 (es)
WO (1) WO1990009780A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU653771B2 (en) * 1991-01-03 1994-10-13 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ATE416755T1 (de) 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6054462A (en) * 1994-04-13 2000-04-25 Janssen Pharmaceutica, N.V. Intranasal antimigraine compositions
HRP950149A2 (en) * 1994-04-13 1997-06-30 Janssen Pharmaceutica Nv Intranasal antimigrene composition
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
SE9403905D0 (sv) * 1994-11-14 1994-11-14 Astra Ab New formulations
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
JP3020141B2 (ja) * 1996-10-07 2000-03-15 株式会社富士薬品 経鼻投与用製剤
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US6730735B2 (en) 1997-07-03 2004-05-04 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Conjugate of polyethylene glycol and chitosan
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
JP3422775B2 (ja) * 1998-07-08 2003-06-30 キリン−アムジエン・インコーポレーテツド 高分子医薬品含有粉末状経粘膜投与製剤
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
EP1416916B1 (en) 2001-08-16 2007-10-17 Cmp Therapeutics Limited Chitin microparticles and their medical uses
EP1441762A1 (en) * 2001-09-28 2004-08-04 University Of South Florida Rsv gene expression vaccine
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
WO2003092618A2 (en) 2002-04-30 2003-11-13 University Of South Florida Materials and methods for prevention and treatment of rna viral diseases
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0310919D0 (en) 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
EP1734938B1 (en) 2004-03-26 2012-06-20 Universita' Degli Studi Di Parma Insulin highly respirable microparticles
US8399025B2 (en) 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
EP1797870A1 (en) * 2005-12-14 2007-06-20 The Jordanian Pharmaceutical Manufacturing Co. Oral delivery of protein drugs using microemulsion
CN102164618A (zh) 2006-03-30 2011-08-24 恩根尼公司 用于体内转染肠细胞的非病毒组合物和方法
AU2007262845B2 (en) 2006-06-20 2013-07-25 Mucovax Inc. Compositions comprising chitin microparticles and their medical uses
WO2008097664A1 (en) 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
WO2009026122A1 (en) * 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
EP2414560B1 (de) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Verfahren zur beschichtung einer oberfläche eines bauteils
JP5763053B2 (ja) 2009-05-18 2015-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アダプタ、吸入器具及びアトマイザ
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
BR112012012475B1 (pt) 2009-11-25 2020-03-03 Boehringer Ingelheim International Gmbh Nebulizador
WO2011160932A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nebulizer
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
LT2825565T (lt) 2012-03-15 2019-07-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Katijoninis polimeras glikogeno pagrindu
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
WO2014055825A1 (en) 2012-10-04 2014-04-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services A formulation of mycobacterial components as an adjuvant for inducing th17 responses
WO2014113541A1 (en) 2013-01-16 2014-07-24 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Attenuated chlamydia vaccine
JP6643231B2 (ja) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
IL247927B (en) 2014-05-07 2022-09-01 Boehringer Ingelheim Int Container, a device that turns a liquid into a fine spray and use
WO2015169430A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Nebulizer
CN116036425A (zh) 2014-05-07 2023-05-02 勃林格殷格翰国际有限公司 喷雾器、指示器装置及容器

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3250023T (es) * 1981-01-14 1990-03-29

Also Published As

Publication number Publication date
CA2045472C (en) 2000-01-04
NO912870D0 (no) 1991-07-23
EP0460020A1 (en) 1991-12-11
DK0460020T3 (da) 1994-05-16
JP3306779B2 (ja) 2002-07-24
DE69008346T2 (de) 1994-08-25
DE69008346T3 (de) 1998-01-08
ATE104545T1 (de) 1994-05-15
EP0460020B2 (en) 1997-09-17
CA2045472A1 (en) 1990-08-26
DE69008346D1 (de) 1994-05-26
ES2055904T5 (es) 1998-01-01
NO912870L (no) 1991-07-23
EP0460020B1 (en) 1994-04-20
NO301692B1 (no) 1997-12-01
GB8904370D0 (en) 1989-04-12
WO1990009780A1 (en) 1990-09-07

Similar Documents

Publication Publication Date Title
ES2055904T3 (es) Composiciones para suministro de farmacos.
AU587281B2 (en) Slow-release pharmaceutical agent
IL114596A (en) Pharmaceutical compositions containing an active substance blended with a carrier process for preparation thereof and their use for preparation of inhalated drugs
NO954582D0 (no) Blanding for nasal administrering av nikotin
BR9911070A (pt) Sistema de liberação de droga compreendendo uma matéria-prima de medicamento sólido acentuadamente compacto
YU46701B (sh) Postupak u za dobijanje osnovnog nosećeg materijala za dozne oblike lekova sa produženim izdvajanjem aktivne supstance
DE3779933D1 (de) Xanthangummienthaltende arzneimittelformulierung mit verzoegerter freisetzung.
DE69022876D1 (de) Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe.
NO870558L (no) Fremgangsmaate for fremstilling av et langsomt frigivende farmasoeytisk preparat.
KR880010758A (ko) 서방성 제제
MY101784A (en) Novel pharmacological compounds
BR9809268A (pt) Unidade de dosagem farmacêutica, processo para fabricação da mesma, e, uso de um produto de amido como um veìculo para unidades de dosagem farmacêutica compreendendo tibolona
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
GB2021409A (en) Pharmaceutical composition
ES2036609T3 (es) Granulado exento de aglutinante con lubricacion retardada del producto activo.
KR880000094A (ko) 위염치료제
KR920016104A (ko) 노인성 특발적 백내장 약제 제조를 위한 칼시토닌의 국소적용 용도 및 이의 약제학적 조성물
KR880012518A (ko) 나프탈-아세트산 유도체를 함유하는 진통 및 소염제약 조성물
BR0010449A (pt) 14beta-h-esteróis, composições farmacêuticas que compreendem os mesmos e uso destes derivados para a preparação de medicamentos reguladores da meiose
BG103023A (en) Bronchodilatation medicamentous form
TH14574A (th) สารผสมทางเภสัชกรรม
JO1519B1 (en) New compounds (new benzimidazole derivatives are effective as ulcers)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 460020

Country of ref document: ES